Treatment of walking impairment in multiple sclerosis: An unmet need for a disease-specific disability

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 10, 2011, Pages 1511-1521

  Panitch, Hillel ^a   Applebee, Angela ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

activities of daily living; dalfampridine; demyelination; disability; immunomodulators; multiple sclerosis; neurofunctional modifiers; potassium channel blocker; quality of life; walking impairment

Indexed keywords

4 AMINOPYRIDINE; BETA1A INTERFERON; CORTICOSTEROID; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; NERISPIRDINE; PLACEBO;

BALANCE IMPAIRMENT; CONFUSION; CORTICOSTEROID THERAPY; DISEASE COURSE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EATON LAMBERT SYNDROME; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; NEUROMUSCULAR TRANSMISSION; PATIENT COMPLIANCE; PHYSICAL CAPACITY; QUALITY OF LIFE; REHABILITATION CARE; RELAPSE; REVIEW; SEIZURE; SPINAL CORD INJURY; WALKING DIFFICULTY;

4-AMINOPYRIDINE; AXONS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS; POTASSIUM CHANNEL BLOCKERS; QUALITY OF LIFE; WALKING;

EID: 79958748171     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.586338     Document Type: Review

References (101)

1. National Multiple Sclerosis Society. About MS. Available from: http://www.nationalmssociety.org/about-multiplesclerosis/index.aspx [Last accessed 15 December 2010]
2. Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis. A cross-sectional study in the United States. Neurology 2006;66:1696-702. (Pubitemid 43964625)
3. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;12:918-26 (Pubitemid 44174075)
4. Waxman SG. Conduction in myelinated, unmyelinated, and demyelinated fibers. Arch Neurol 1977;34:585-9 (Pubitemid 8199510)
5. Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000;123:171-84 (Pubitemid 30037979)
6. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70 (Pubitemid 32053209)
7. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999;12:295-302 (Pubitemid 29378163)
8. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003;206:165-71 (Pubitemid 36143722)
9. Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985;328:358-61 (Pubitemid 15135163)
10. Nortvedt MW, Riise T, Frugard J, et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler 2007;13:106-12 (Pubitemid 46152768)
11. Nortvedt MW, Riise T, Myhr KM, et al. Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler 2001;7:231-5 (Pubitemid 32780693)
12. Brochet B, Deloire MS, Ouallet JC, et al. Pain and quality of life in the early stages after multiple sclerosis diagnosis: a 2-year longitudinal study. Clin J Pain 2009;25:211-17
13. Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000;6:181-5 (Pubitemid 30392116)
14. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-46 (Pubitemid 19056478)
15. Myhr KM, Riise T, Vedeler C, et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler 2001;7:59-65 (Pubitemid 32396580)
16. Hobart JC, Lamping DL, Fitzpatrick R, et al. The Multiple Sclerosis Impact Scale (MSIS 29). A new patient-based outcome measure. Brain 2001;124:962-73 (Pubitemid 32458508)
17. Swingler RJ, Compston DA. The morbidity of multiple sclerosis. Q J Med 1992;83:325-37
18. Hemmett L, Holmes J, Barnes M, et al. What drives quality of life in multiple sclerosis? Q J Med 2004;97:671-6 (Pubitemid 39359325)
19. Goodman AD, Brown TR, Cohen JA, et al. Dose-comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71:1134-41
20. Goodman AD, Brown TR, Krupp L, et al. Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373(9665):732-8
21. Goodman AD, Brown TR, Edwards KR, et al. A Phase III trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68:494-502
22. Miller AE. Early treatment of multiple sclerosis. MSQR - Multiple Sclerosis Quarterly Report 2000;19:7-9
23. Comi G. Why treat early multiple sclerosis patients? Curr Opin Neurol 2000;13:235-40 (Pubitemid 30406528)
24. Frohman EM, Havrdova E, Lublin F, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 2006;63:614-19
25. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4
26. Freedman MS, Hughes B, Mikol DD, et al. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur Neurol 2008;60:1-11. (Pubitemid 351799060)
27. Rovaris M, Confavreux C, Furlan R, et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006;5:343-54
28. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007;6:903-12 (Pubitemid 47405002)
29. Goodin DS, Frohman EM, Garmany Jr GP, et al. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the american academy of neurology and the ms council for clinical practice guidelines. Neurology 2002;58:169-78 (Pubitemid 34086933)
30. National Multiple Sclerosis Society. Expert Opinion Paper. Disease management consensus statement. Treatment recommendations for physicians. Available from: http://www.nationalmssociety.org/for-professionals/healthcare- professionals/publications/expert-opinion-papers/index.aspx [Last accessed 15 December 2010].
31. Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52 (Pubitemid 46824250)
32. Minden S, Hoaglin D, Jureidini S, et al. Disease-modifying agents in the Sonya slifka longitudinal multiple sclerosis study. Mult Scler 2008;14:640-55. (Pubitemid 351954407)
33. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256:568-76.
34. Turner AP, Williams RM, Sloan AP, et al. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Rehabil Psychol 2009;54:116-21
35. Henze T, Rieckmann P, Toyka KV. Multiple sclerosis therapy consensus group of the german multiple sclerosis society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol 2006;56:78-105 (Pubitemid 44492163)
36. Cohen BA. Identification, causation, alleviation, and prevention of complications (ICAP): an approach to symptom and disability management in multiple sclerosis. Neurology 2008;71(24 Suppl 3):S14-20
37. Henze T. What is new in symptom management? Int Mult Scler J 2007;14:22-7 (Pubitemid 46917296)
38. Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol 2010;9:1182-99
39. Milligan N, Newcombe R, Compston D. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-16 (Pubitemid 17067536)
40. Patzold T, Schwengelbeck M, Ossege LM, et al. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol Scand 2002;105:164-8 (Pubitemid 34258956)
41. Hobart JC, Riazi A, Lamping DL, et al. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003;60:31-6 (Pubitemid 36070640)
42. Humm AM, ZAGraggen WJ, Buhler R, et al. Quantification of central motor conduction deficits in multiple sclerosis patients before and after treatment of acute exacerbation by methylprednisolone. J Neurol Neurosurg Psychiatry 2006;77:345-50
43. Brown TR, Kraft GH. Exercise and rehabilitation for individuals with multiple sclerosis. Phys Med Rehabil Clin N Am 2005;16:513-55 (Pubitemid 40704682)
44. Khan F, Turner-Stokes L, Ng L, et al. Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev 2007;2:CD006036
45. Paltamaa J, Sarasoja T, Leskinen E, et al. Measures of physical functioning predict self-reported performance in self-care, mobility, and domestic life in ambulatory persons with multiple sclerosis. Arch Phys Med Rehabil 2007;88:1649-57 (Pubitemid 350151390)
46. Wu N, Minden SL, Hoaglin DC, et al. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm 2007;30:233-67
47. Jones CA, Pohar SL, Warren S, et al. The burden of multiple sclerosis: a community health survey. Health Qual Life Outcomes 2008;6:1
48. Julian LJ, Vella L, Vollmer T, et al. Employment in multiple sclerosis: exiting and re-entering the work force. J Neurol 2008;255:1354-60
49. Motl RW, Snook EM, Schapiro RT. Symptoms and physical activity behavior in individuals with multiple sclerosis. Res Nurs Health 2008;31:466-75
50. Salter A, Cutter GR, Tyry T, et al. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin 2010;26:493-500.
51. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler 1999;5:349-54 (Pubitemid 29505050)
52. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52 (Pubitemid 14237132)
53. Marrie RA, Goldman M. Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler 2007;13:1176-82 (Pubitemid 351541422)
54. Sharrack B, Hughes RAC, Soudain S, et al. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 1999;122:141-59 (Pubitemid 29046280)
55. Hobart JC, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000;23:1027-40 (Pubitemid 30224198)
56. Martin CL, Phillips BA, Kilpatrick TJ, et al. Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler 2006;12:620-8 (Pubitemid 46947926)
57. Johansson S, Ytterberg C, Claesson IM, et al. High concurrent presence of disability in multiple sclerosis. Associations with perceived health. J Neurol 2007;254:767-73 (Pubitemid 47012454)
58. Einarsson U, Gottberg K, Von Koch L, et al. Cognitive and motor function in people with multiple sclerosis in Stockholm County. Mult Scler 2006;12:340-53 (Pubitemid 43827191)
59. Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006;111:224-59. (Pubitemid 43765538)
60. Purves D, Augustine JG, Fitzpatrick D, et al. editors. Neuroscience, 4th edn. Sunderland, MA: Sinauer Associates, 2008
61. Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980;283:570-2 (Pubitemid 10136031)
62. Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989;22:47-52
63. Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997;77:553-62 (Pubitemid 27079623)
64. Lundh H. Effects of 4-aminopyridine on neuromuscular transmission. Brain Res 1978;153:307-18 (Pubitemid 8387960)
65. Kim YI, Goldner MM, Sanders DB. Facilitatory effects of 4-aminopyridine on neuromuscular transmission in disease states. Muscle Nerve 1980;3:112-19 (Pubitemid 10134617)
66. Dunn J, Blight A. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin; In press
67. Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol 1981;313:301-15 (Pubitemid 11125577)
68. United States Food and Drug Administration. Report: 2006 Limited FDA Survey of Compounded Drug Products. Available from: http://www.fda.gov/Drugs/ Guidance ComplianceRegulatoryInformation/PharmacyCompounding/ucm204237.htm [Last accessed 15 December 2010]
69. Spyker DA, Lynch C, Shabanowitz J, et al. Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol 1980;16:487-97 (Pubitemid 10048631)
70. Stork CM, Hoffman RS. Characterization of 4-aminopyridine in overdose. J Toxicol Clin Toxicol 1994;32:583-7 (Pubitemid 24332007)
71. Smeets JW, Kunst MW. Severe poisoning by 4-aminopyridine in a body builder. Ned Tijdschr Geneeskd 1995;139:2667-9 (Pubitemid 26021056)
72. Pickett TA, Enns R. Atypical presentation of 4-aminopyridine overdose. Ann Emerg Med 1996;27:382-5 (Pubitemid 26085022)
73. Johnson NC, Morgan MW. An unusual case of 4-aminopyridine toxicity. J Emerg Med 2006;30:175-7
74. Badruddin A, Menon RS, Reder AS. 4-Aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis. Neurology 2009;72:1100-1
75. Burton JM, Bell CM, Walker SE, OConnor PW. 4-Aminopyridine toxicity with unintentional overdosage in four patients with multiple sclerosis. Neurology 2008;71:1833-4
76. De Cauwer H, De Wolf P, Couvreur F, et al. An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? Acta Neurol Belg 2009;109:40-1
77. Schwam E. Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med May 2009 [Epub ahead of print]
78. Lundh H, Nilsson O, Rosen I. Effects of 4-aminopyridine in myasthenia gravis. J Neurol Neurosurg Psychiatry 1979;42:171-5 (Pubitemid 9110873)
79. Lundh H, Nilsson O, Rosén I. 4-aminopyridine - a new drug tested in the treatment of Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry 1977;40:1109-12 (Pubitemid 8261762)
80. Agoston S, van Weerden T, Westra P, et al. Effects of 4-aminopyridine in Eaton Lambert Syndrome. Br J Anaesth 1978;50:383-5 (Pubitemid 9055537)
81. Hansebout RR, Blight AR, Fawcett S, et al. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma 1993;10:1-18 (Pubitemid 23153141)
82. Potter PJ, Hayes KC, Hsieh JT, et al. Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases. Spinal Cord 1998;36:147-55 (Pubitemid 28120689)
83. Segal JL, Pathak MS, Hernandez JP, et al. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial. Pharmacotherapy 1999;19:713-23 (Pubitemid 29277971)
84. van der Bruggen MA, Huisman HB, Beckerman H, et al. Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury. J Neurol 2001;248:665-71 (Pubitemid 32695862)
85. Cardenas DD, Ditunno J, Graziani V, et al. Phase II trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord 2007;45:158-68 (Pubitemid 46204264)
86. Stefoski D, Davis FA, Faut M, et al. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987;21:71-7 (Pubitemid 17004147)
87. Schwid SR, Petrie MD, McDermott MP, et al. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48:817-21
88. Bever CT Jr, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994;44:1054-9 (Pubitemid 24188176)
89. Van Diemen HA, Polman CH, van Dongen TM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992;32:123-30
90. Van Diemen HA, Polman CH, Koetsier JC, et al. 4-aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 1993;16:195-204 (Pubitemid 23149956)
91. Vollmer T, Henney HR 3rd. Pharmacokinetics and tolerability of single administration, escalating doses of 4-aminopyridine slow release in subjects with multiple sclerosis. Clin Ther 2009;31:2206-14
92. Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double blind, placebo-controlled, dose-ranging study. Mult Scler 2007;13:357-68 (Pubitemid 46705997)
93. Schwid SR, Goodman AD, McDermott MP, et al. Quantitative functional measures in MS: what is a reliable change? Neurology 2002;58:1294-6 (Pubitemid 34411881)
94. Hoogervorst EL, Kalkers NF, Cutter GR, et al. The patients perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler 2004;10:55-60 (Pubitemid 38100527)
95. Kragt JJ, van der Linden FA, Nielsen JM, et al. Clinical impact of 20% worsening on timed 25-foot walk and 9-hole peg test in multiple sclerosis. Mult Scler 2006;12:594-8 (Pubitemid 46940633)
96. Bosma LV, Kragt JJ, Brieva L, et al. Progression on the multiple sclerosis functional composite in multiple sclerosis: what is the optimal cut-off for the three components? Mult Scler 2010;16:862-7
97. Brown TR, Schapiro RT, Edwards KR, et al.; on behalf of the MS-F202, MS-F203, MS-F204 Study Groups. Response to treatment with dalfampridine extended release tablets in patients with multiple sclerosis is independent of baseline patient characteristics and concomitant immunomodulator therapy [P06.136]. Poster presented at the 62nd Annual Meeting of the American Academy of Neurology, 10 - 17 April 2010, Toronto, Ontario, Canada
98. Ampyra (dalfampridine extended release tablets) [prescribing information]. Hawthorne, NY: Acorda Therapeutics, Inc., January 2010
99. Goodman A, Brown T, Edwards K, Schapiro R; for the MS-F203, MS-F204, MS-F203EXT, and MS-F204EXT Study Groups. Analysis of open-label extension studies of prolonged release fampridine tablets in multiple sclerosis [abstract]. Mult Scler 2010;16(Suppl):S17
100. Smith C, Kongsamut S, Wang H, et al. In vitro electrophysiological activity of nerispirdine, a novel 4-aminopyridine derivative. Clin Exp Pharmacol Physiol 2009;36:1104-9
101. Clinicaltrials.gov. Efficacy, safety, and tolerability of nerispirdine in patients with multiple sclerosis. sanofi-aventis [NCT00811902]. Available from: http://clinicaltrials.gov/ct2/show/NCT00811902?term=nerispirdine&rank=1 [Last accessed 15 December 2010]